Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack
Alan
A
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Alan.Pollack@FCCC.edu
Horwitz
Eric M
EM
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D017273:Goserelin / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D016729:Leuprolide